Pioneering a disruptive
therapeutic modality
Transformative medicines for
Deubiquitination Therapeutics
Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. We are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drugging targets by establishing a powerful small-molecule modality for a wide variety of devastating diseases.
THE BIG IDEA
Aberrant ubiquitination is a driver of disease.
This could be due to a number of reasons:
-
Excessive protein degradation
-
Localization of proteins in the “wrong” compartment
-
Pathway activation through primary ubiquitination step
Targeted deubiquitination can be beneficial to address these issues and restore normal function.
THE CHALLENGE
Drugging a universal post translational signal – ubiquitin – in a target-specific manner
THE SOLUTION
Establishing an adaptable platform for restoring protein stability and normal function
Reduced protein expression and aberrant activation of cell growth and immune signaling cascades are common underlying drivers of disease. Genetic mutations can reduce the stability of proteins with essential function; tumor cells often eliminate key regulatory factors to grow unchecked; pathogens co-opt the host ubiquitin-proteasome system (UPS) to modulate immune response. Ubiquitin is the master regulator of protein lifecycle and activity, involved in both protein degradation and protein activation and signaling. Deubiquitinases (DUBs) are nature’s ubiquitin editors, involved in broad biological activities, and have emerged as a highly sought-after therapeutic target.
Our Approach
At Stablix, we are establishing a new paradigm for tackling diverse diseases by harnessing the power of the body’s own cellular machinery. We generate heterobifunctional small molecules that selectively recruit active deubiquitinases (DUBs) to target proteins to precisely remove ubiquitin. Targeting proteins subject to aberrant ubiquitination restores deficient proteins to therapeutic levels alternatively restores normal function. We are leveraging targeted deubiquitination to develop programs to treat cancer, rare diseases and immunological disorders.
Who We Are
Stablix, co-located at sites in New York City and Boston, is a preclinical stage biotechnology company, pioneering small molecule medicines for targeted deubiquitination therapeutics. We are an experienced, multi-disciplinary team with a combined power of industry knowledge and creative talent.
Leadership
Eddine Saiah, PhD
CEO and President
Scientific Advisors
Henry Colecraft, PhD
Chair of SAB
Co-Founder
Benedikt Kessler, PhD
University of Oxford
Professor
Scott Kanner, PhD
Scientific Advisor
Co-Founder
Andrew Turnbull, PhD
Senior Principal Scientist
CRUK-TDL
Board of Directors
Carlo Rizzuto, PhD
Director
J.C. Lopez, MD
Observer
Ali Behbahani, MD
Director
Bihua Chen
Observer
Eddine Saiah
Director
Ezana Demissie
Observer
Stablix Team
Jamie Palme
Head of Finance and Operations
Kap-Sun Yeung
Senior Director, Head of Chemistry
Subha Vogeti
Principal Scientist, Biology
Wendy Lee
Associate Director, Biology
Tyler Mann
Senior Scientist, Chemistry
Mahesh Vishe
Senior Scientist, Chemistry
Jan Reiling
Principal Scientist, Biology
Sharan Swarup
Senior Scientist, Biology
Our Investors
